Scholarlink

<p>Programmed cell death ligand-1 (PD-L1) is involved in T-cell regulation by acting as an immune checkpoint inhibitor, and its expression is being widely studied in various malignancies. The following study was designed to examine the role of PD-L1 and its association with HPV in oral squamous cell carcinomas in the Indian population. Immunohistochemistry for PD-L1 and p16 was done on the resection specimens. Combined positive score (CPS) was evaluated for PD-L1; a CPS <i>≥</i> 1and &lt; 20 was considered low-positive, and a CPS <i>≥</i> 20 was considered strong positive. Diffuse and strong nuclear and cytoplasmic expression of p16 in <i>≥</i> 70% tumor cells was considered positive (block) expression. A total of 188 cases were included in the study. PD-L1 expression was seen in a total of 86.1% (162 cases); of these, 67.02% (126 cases) showed strong expression of PD-L1 with a CPS <i>≥</i> 20. A significant correlation was observed between PD-L1 expression and tumor stage, with higher PD-L1 expression in advanced stages T2-4 compared to T1 (p-value = 0.014). No significant correlation of PD-L1 with p16 positivity, lymph node metastases, or tumor grade was observed. High PD-L1 expression was observed in more than 80% of cases, regardless of HPV status, suggesting that targeted immunotherapy with PD-L1 inhibitors can be an effective treatment in the Indian subpopulation, especially in those with advanced-stage tumors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pd-L1 Expression in Oral Cavity Squamous Cell Carcinomas

  • 期刊论文

  • 发表日期：

    2026年3月13日

查看全文
  • Aasma Nalwa,
  • Aarathi Visakhan,
  • Poonam Abhay Elhence,
  • Meenakshi Rao,
  • Vikarn Vishwajeet,
  • Akhil Dhanesh Goel

摘要

Programmed cell death ligand-1 (PD-L1) is involved in T-cell regulation by acting as an immune checkpoint inhibitor, and its expression is being widely studied in various malignancies. The following study was designed to examine the role of PD-L1 and its association with HPV in oral squamous cell carcinomas in the Indian population. Immunohistochemistry for PD-L1 and p16 was done on the resection specimens. Combined positive score (CPS) was evaluated for PD-L1; a CPS ≥ 1and < 20 was considered low-positive, and a CPS ≥ 20 was considered strong positive. Diffuse and strong nuclear and cytoplasmic expression of p16 in ≥ 70% tumor cells was considered positive (block) expression. A total of 188 cases were included in the study. PD-L1 expression was seen in a total of 86.1% (162 cases); of these, 67.02% (126 cases) showed strong expression of PD-L1 with a CPS ≥ 20. A significant correlation was observed between PD-L1 expression and tumor stage, with higher PD-L1 expression in advanced stages T2-4 compared to T1 (p-value = 0.014). No significant correlation of PD-L1 with p16 positivity, lymph node metastases, or tumor grade was observed. High PD-L1 expression was observed in more than 80% of cases, regardless of HPV status, suggesting that targeted immunotherapy with PD-L1 inhibitors can be an effective treatment in the Indian subpopulation, especially in those with advanced-stage tumors.